| Wissenschaftl. Titel | A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long-term treatment-free follow-up period for up to an additional 3 years |
| Erkrankung |
Haut:
Nesselsucht (Urtikaria) und Erytheme
Kinder: Hauterkrankungen |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Zu den Ein- und Ausschlusskriterien |
erstellt 25.01.2024 Admin03
geändert 01.08.2024 Admin04